Tulane Outbreak Daily – November 6, 2020

Featured Headlines

For the first time, U.S. sees 100,000 new cases in one day – NBC News

The number of new coronavirus cases recorded in a single day in the United States topped 100,000 for the first time Wednesday, setting a record in the monthslong pandemic, NBC News data show.

The US hit 120,000 new COVID cases on Thursday, breaking records for the second day in a row – Popular Science

On Thursday the United States hit an all-time high for new cases of COVID-19 for the second day in a row, reaching more than 120,000 diagnoses after surpassing 100,000 for the first time on Wednesday.

Covid-19 hospitalizations soar, causing fears that death rates will climb soon – CNN

As nationwide coronavirus cases soar, the number of hospitalized Americans is also climbing, and experts warn that could lead to a rise in deaths.
The United States has more than 53,000 Covid-19 patients, according to the COVID Tracking Project.

Telework Before Illness Onset Among Symptomatic Adults Aged ≥18 Years With and Without COVID-19 in 11 Outpatient Health Care Facilities — United States, July 2020 – CDC

Why COVID-19 Might Get Worse in Winter, Just Like Flu – MedPageToday

Grandma’s adage that you can catch the flu from the cold weather is not without merit. This association is undoubtedly evident for COVID-19, whose incidence is predicted to continue to increase exponentially as winter approaches.

ECDC to assess risk associated with spread of SARS-CoV-2 in mink farms – ECDC

When the virus is introduced into a mink farm, it can spread quickly, leading to many cases among mink. Due to the large number of infections and possibly due to biological differences between mink and humans, the virus can accumulate mutations. Such variants have the possibility to spread back into the human population.

Parts Of Northern Denmark On Lockdown Over Coronavirus Variant Outbreak In Minks – NPR

Denmark is putting over a quarter of a million of residents on lockdown after discovering coronavirus outbreaks among bred minks, including a mutated strain.

Travel on Thanksgiving? Pass the COVID – Kaiser News

Molly Wiese was truly stumped. Her parents and siblings live in Southern California, and Wiese, a 35-year-old lawyer, has returned home every Christmas since she moved to Minnesota in 2007. Because of the pandemic, Wiese thought it would be wiser to stay put for once. But in June, Wiese’s father was diagnosed with stage 4 cancer, and they feared this could be his final holiday season.

First It Was Masks; Now Some Refuse Testing for SARS-CoV-2 – JAMA

In the pandemic’s early weeks, when a shortage of tests meant that mainly hospitalized patients were being tested, the demand was greater than the supply. Months later, laboratories have greater testing capacity, but in some states, testing rates have dropped as cases have increased.

Dining bubbles are popping up everywhere, but are they safe? Experts weigh in. – Washington Post

Whatever you call them, the clear, igloo-like structures have started popping up in U.S. cities where colder weather threatens the outdoor dining that restaurants have turned to in their attempt to stay afloat during the coronavirus pandemic.

Clinical Considerations

COVID-Related Strokes Especially Severe, Result in Worse Outcomes – MedPageToday

Ischemic strokes in COVID-19 patients tended to be more severe than those in other individuals, according to a case-control study from the U.K.

Official Reporting for November 6, 2020

World Health Organization

Weekly Epi Update November 6, 2020 (Last Updated)

Confirmed Cases: 48,534,508

Deaths: 1,231,017

ECDC

Confirmed Cases: 48 763 203

Deaths: 1 234 371

Johns Hopkins

Confirmed Cases: 49,237,148
Deaths: 1,241,378

Centers for Disease Control and Prevention (CDC)

Total cases: 9,581,770
Total deaths: 234,264

Surveillance Headlines

UNITED STATES

US: Coronavirus cases at U.S. colleges have hit a quarter million. – NYT

Alaska: Hit hardest by COVID-19, Alaska’s Pacific Islanders face death and severe illness at an alarming rate – Alaska Public Media

Texas: Poised to hit 1 million Covid-19 cases, the most in the nation – NBC

EUROPE

Italy: Italy imposes regional lockdown as Europe battles surges – BBC

UK & Greece: England begins a new lockdown, and Greece will soon follow – NYT

France: France Posts Record New Virus Cases as Minister Warns of ‘Violent’ Second Wave – Bloomberg

Science and Tech

Virus that causes COVID-19 puts a plug in cellular defenses – Science Daily

One of the novel coronavirus’ most insidious tricks is that it can block the ability of cells to produce protective proteins without hindering its own ability to replicate.

Enzyme targeted by virus also influences gut inflammation – Science Daily

An enzyme that helps COVID-19 (coronavirus) infect the body also plays a role in inflammation and patient outcomes in inflammatory bowel disease (IBD), according to a new study. The findings raise the possibility that anti-inflammatory drug therapies for IBD may aid recovery from coronavirus.

Diagnostics

FDA Authorizes First Test that Detects Neutralizing Antibodies from Recent or Prior SARS-CoV-2 Infection – FDA

Today, the U.S. Food and Drug Administration authorized the first serology test that detects neutralizing antibodies from recent or prior SARS-CoV-2 infection, which are antibodies that bind to a specific part of a pathogen and have been observed in a laboratory setting to decrease SARS-CoV-2 viral infection of cells. The FDA issued an emergency use authorization (EUA) for the cPass SARS-CoV-2 Neutralization Antibody Detection Kit, which specifically detects this type of antibody.

Therapeutics

Fauci, NIAID Look to Past to Inform Future of COVID-19 Therapies – MedPageToday

In developing therapeutic agents for COVID-19, researchers learned from the lessons of past viruses, from HIV to Ebola to even flu, experts at an NIH webinar said. Clinical agents in development for SARS-CoV-2 include antivirals and host targeted/immunomodulators, as well as neutralizing monoclonal antibodies. And randomized trials are still the best way to determine whether they work, experts said.

Psychological and Sociological Impact

None Today

Published Research

Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals – Science

Surgery during the COVID-19 pandemic – The Lancet

Pre-Print Studies

None Today

Misinformation, Disinformation, and Conspiracy Theories

Managing the COVID-19 vaccine infodemic – The Lancet

If you read News Punch (aka “Where mainstream fears to tread”), you will be familiar with a series of articles about the prospects for a COVID-19 vaccine. With headlines such as “Big Pharma Exec: We Are Exempt From COVID-19 Vaccine Liability Claims”, the website has published report after report casting doubt on the integrity of vaccine science and even the likelihood of a vaccine becoming available. You will find similar pieces on other websites, such as Infowars and AlterNet. The arguments these articles peddle seem deliberately designed to sow uncertainty. Elon Musk is alleged to have said that he won’t allow his children to receive a COVID-19 vaccine. Executives from one vaccine manufacturer are alleged to have sold “millions in stock as Covid vaccine trials enter phase 3”. Doctors are accused of demanding the US Government punish Americans who refuse a COVID-19 vaccine. These stories may be having an effect. Last month, Nature Medicine published the results of a survey describing the views of over 13 000 people across 19 countries. 14·2% of the respondents completely or somewhat disagreed with the statement that they would accept a COVID-19 vaccine if generally available. 17·9% completely or somewhat disagreed with the statement that they would accept a COVID-19 vaccine if their employer recommended it. In many countries, vaccine hesitancy is sufficiently high to render community immunity a challenging goal. The survey suggests that far too little has been done to prepare the public for the arrival of a COVID-19 vaccine.

Coping in 2020

Leave a Reply

Your email address will not be published. Required fields are marked *